Role of cytoreductive surgery in the management of peritoneal metastases for gastrointestinal stromal tumors

Peritoneal GIST metastases offer a better prognosis than other sarcomas. According to the sources, tyrosine kinase inhibitors are the mandatory first-line treatment. In responding cases, cytoreductive surgery performed after 6–12 months of therapy can significantly improve long-term survival rates. Multidisciplinary teams at experienced centers should manage these complex cases to integrate respectability, expert oncologic response, and individualized patient conditions.